Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: Outcome of the patients alive after a 6-year follow-up

Francesca Palandri, Fausto Castagnetti, Nicoletta Testoni, Simona Luatti, Giulia Marzocchi, Simona Bassi, Massimo Breccia, Giuliana Alimena, Ester Pungolino, Giovanna Rege-Cambrin, Riccardo Varaldo, Maurizio Miglino, Giorgina Specchia, Eliana Zuffa, Felicetto Ferrara, Monica Bocchia, Giuseppe Saglio, Fabrizio Pane, Daniele Alberti, Giovanni MartinelliMichele Baccarani, Gianantonio Rosti

Research output: Contribution to journalArticle

Abstract

Background: Imatinib mesylate is the first line treatment for chronic myeloid leukemia. In patients with advanced phase of the disease, the advent of imatinib significantly increased survival. However, few long-term data, based on large, prospective and controlled trials are available on the outcome of these patients. Design and Methods: We conducted a phase II trial of imatinib 600 mg daily in patients with chronic myeloid leukemia in blast crisis. The return to chronic phase was defined as

Original languageEnglish
Pages (from-to)1792-1796
Number of pages5
JournalHaematologica
Volume93
Issue number12
DOIs
Publication statusPublished - Dec 2008

Fingerprint

Blast Crisis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Survival
Imatinib Mesylate
Therapeutics

Keywords

  • Blast crisis
  • Chronic myeloid leukemia
  • Imatinib
  • Long-term
  • Outcome

ASJC Scopus subject areas

  • Hematology

Cite this

Palandri, F., Castagnetti, F., Testoni, N., Luatti, S., Marzocchi, G., Bassi, S., ... Rosti, G. (2008). Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: Outcome of the patients alive after a 6-year follow-up. Haematologica, 93(12), 1792-1796. https://doi.org/10.3324/haematol.13068

Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg : Outcome of the patients alive after a 6-year follow-up. / Palandri, Francesca; Castagnetti, Fausto; Testoni, Nicoletta; Luatti, Simona; Marzocchi, Giulia; Bassi, Simona; Breccia, Massimo; Alimena, Giuliana; Pungolino, Ester; Rege-Cambrin, Giovanna; Varaldo, Riccardo; Miglino, Maurizio; Specchia, Giorgina; Zuffa, Eliana; Ferrara, Felicetto; Bocchia, Monica; Saglio, Giuseppe; Pane, Fabrizio; Alberti, Daniele; Martinelli, Giovanni; Baccarani, Michele; Rosti, Gianantonio.

In: Haematologica, Vol. 93, No. 12, 12.2008, p. 1792-1796.

Research output: Contribution to journalArticle

Palandri, F, Castagnetti, F, Testoni, N, Luatti, S, Marzocchi, G, Bassi, S, Breccia, M, Alimena, G, Pungolino, E, Rege-Cambrin, G, Varaldo, R, Miglino, M, Specchia, G, Zuffa, E, Ferrara, F, Bocchia, M, Saglio, G, Pane, F, Alberti, D, Martinelli, G, Baccarani, M & Rosti, G 2008, 'Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: Outcome of the patients alive after a 6-year follow-up', Haematologica, vol. 93, no. 12, pp. 1792-1796. https://doi.org/10.3324/haematol.13068
Palandri, Francesca ; Castagnetti, Fausto ; Testoni, Nicoletta ; Luatti, Simona ; Marzocchi, Giulia ; Bassi, Simona ; Breccia, Massimo ; Alimena, Giuliana ; Pungolino, Ester ; Rege-Cambrin, Giovanna ; Varaldo, Riccardo ; Miglino, Maurizio ; Specchia, Giorgina ; Zuffa, Eliana ; Ferrara, Felicetto ; Bocchia, Monica ; Saglio, Giuseppe ; Pane, Fabrizio ; Alberti, Daniele ; Martinelli, Giovanni ; Baccarani, Michele ; Rosti, Gianantonio. / Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg : Outcome of the patients alive after a 6-year follow-up. In: Haematologica. 2008 ; Vol. 93, No. 12. pp. 1792-1796.
@article{234bf906e4774e5f8980059e0a23398e,
title = "Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: Outcome of the patients alive after a 6-year follow-up",
abstract = "Background: Imatinib mesylate is the first line treatment for chronic myeloid leukemia. In patients with advanced phase of the disease, the advent of imatinib significantly increased survival. However, few long-term data, based on large, prospective and controlled trials are available on the outcome of these patients. Design and Methods: We conducted a phase II trial of imatinib 600 mg daily in patients with chronic myeloid leukemia in blast crisis. The return to chronic phase was defined as",
keywords = "Blast crisis, Chronic myeloid leukemia, Imatinib, Long-term, Outcome",
author = "Francesca Palandri and Fausto Castagnetti and Nicoletta Testoni and Simona Luatti and Giulia Marzocchi and Simona Bassi and Massimo Breccia and Giuliana Alimena and Ester Pungolino and Giovanna Rege-Cambrin and Riccardo Varaldo and Maurizio Miglino and Giorgina Specchia and Eliana Zuffa and Felicetto Ferrara and Monica Bocchia and Giuseppe Saglio and Fabrizio Pane and Daniele Alberti and Giovanni Martinelli and Michele Baccarani and Gianantonio Rosti",
year = "2008",
month = "12",
doi = "10.3324/haematol.13068",
language = "English",
volume = "93",
pages = "1792--1796",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "12",

}

TY - JOUR

T1 - Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg

T2 - Outcome of the patients alive after a 6-year follow-up

AU - Palandri, Francesca

AU - Castagnetti, Fausto

AU - Testoni, Nicoletta

AU - Luatti, Simona

AU - Marzocchi, Giulia

AU - Bassi, Simona

AU - Breccia, Massimo

AU - Alimena, Giuliana

AU - Pungolino, Ester

AU - Rege-Cambrin, Giovanna

AU - Varaldo, Riccardo

AU - Miglino, Maurizio

AU - Specchia, Giorgina

AU - Zuffa, Eliana

AU - Ferrara, Felicetto

AU - Bocchia, Monica

AU - Saglio, Giuseppe

AU - Pane, Fabrizio

AU - Alberti, Daniele

AU - Martinelli, Giovanni

AU - Baccarani, Michele

AU - Rosti, Gianantonio

PY - 2008/12

Y1 - 2008/12

N2 - Background: Imatinib mesylate is the first line treatment for chronic myeloid leukemia. In patients with advanced phase of the disease, the advent of imatinib significantly increased survival. However, few long-term data, based on large, prospective and controlled trials are available on the outcome of these patients. Design and Methods: We conducted a phase II trial of imatinib 600 mg daily in patients with chronic myeloid leukemia in blast crisis. The return to chronic phase was defined as

AB - Background: Imatinib mesylate is the first line treatment for chronic myeloid leukemia. In patients with advanced phase of the disease, the advent of imatinib significantly increased survival. However, few long-term data, based on large, prospective and controlled trials are available on the outcome of these patients. Design and Methods: We conducted a phase II trial of imatinib 600 mg daily in patients with chronic myeloid leukemia in blast crisis. The return to chronic phase was defined as

KW - Blast crisis

KW - Chronic myeloid leukemia

KW - Imatinib

KW - Long-term

KW - Outcome

UR - http://www.scopus.com/inward/record.url?scp=57349124075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57349124075&partnerID=8YFLogxK

U2 - 10.3324/haematol.13068

DO - 10.3324/haematol.13068

M3 - Article

C2 - 18838477

AN - SCOPUS:57349124075

VL - 93

SP - 1792

EP - 1796

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 12

ER -